{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:40:42Z","timestamp":1789515642332,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medivation, Inc."},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1111\/jcpt.12503","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T04:36:36Z","timestamp":1488429396000},"page":"268-275","source":"Crossref","is-referenced-by-count":9,"title":["A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects"],"prefix":"10.1155","volume":"42","author":[{"given":"W.","family":"Krauwinkel","sequence":"first","affiliation":[{"name":"Astellas Pharma Europe; Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Noukens","sequence":"additional","affiliation":[{"name":"Kinesis Pharma BV; Breda The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe; Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Popa","sequence":"additional","affiliation":[{"name":"ARENSIA Exploratory Medicine; Republican Clinical Hospital; Chisinau Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ouatas","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe; Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe; Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Phung","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe; Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Medivation, Inc., (Medivation was acquired by Pfizer, Inc. in September 2016); San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mordenti","sequence":"additional","affiliation":[{"name":"Medivation, Inc., (Medivation was acquired by Pfizer, Inc. in September 2016); San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mateva","sequence":"additional","affiliation":[{"name":"Gastroenterology Clinic; University Hospital St. Ivan Rilski; Medical University Sofia; COMAC Medical Ltd; Sofia Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"10.1111\/jcpt.12503-BIB0001|jcpt12503-cit-0001","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1111\/jcpt.12503-BIB0002|jcpt12503-cit-0002","unstructured":"Astellas Pharma US, Inc., Medivation, Inc XTANDI US Prescribing Information http:\/\/www.astellas.us\/docs\/us\/12A005-ENZ-WPI.pdf?v=1"},{"key":"10.1111\/jcpt.12503-BIB0003|jcpt12503-cit-0003","unstructured":"Astellas Pharma US, Inc., Medivation, Inc. Xtandi Summary of Product Characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002639\/WC500144996.pdf"},{"key":"10.1111\/jcpt.12503-BIB0004|jcpt12503-cit-0004","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12503-BIB0005|jcpt12503-cit-0005","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12503-BIB0006|jcpt12503-cit-0006","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40262-015-0271-5","article-title":"Clinical pharmacokinetic studies of enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12503-BIB0007|jcpt12503-cit-0007","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","article-title":"Pharmacokinetic drug interaction studies with enzalutamide","volume":"54","author":"Gibbons","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12503-BIB0008|jcpt12503-cit-0008","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2165\/00003088-199937050-00004","article-title":"Effects of liver disease on pharmacokinetics. An update","volume":"37","author":"Rodighiero","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12503-BIB0009|jcpt12503-cit-0009","unstructured":"American Cancer Society Cancer Facts & Figures 2015 http:\/\/www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2015\/index"},{"key":"10.1111\/jcpt.12503-BIB0010|jcpt12503-cit-0010","doi-asserted-by":"publisher","first-page":"8459","DOI":"10.3748\/wjg.v19.i46.8459","article-title":"Liver physiology and liver diseases in the elderly","volume":"19","author":"Tajiri","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1111\/jcpt.12503-BIB0011|jcpt12503-cit-0011","unstructured":"European Medicines Agency Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003122.pdf"},{"key":"10.1111\/jcpt.12503-BIB0012|jcpt12503-cit-0012","unstructured":"US Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) et al Guidance for Industry: Pharmacokinetics in Patients with Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072123.pdf"},{"key":"10.1111\/jcpt.12503-BIB0013|jcpt12503-cit-0013","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"10.1111\/jcpt.12503-BIB0014|jcpt12503-cit-0014","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4155\/bio.13.325","article-title":"Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC-MS\/MS","volume":"6","author":"Bennett","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1111\/jcpt.12503-BIB0015|jcpt12503-cit-0015","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"10.1111\/jcpt.12503-BIB0016|jcpt12503-cit-0016","unstructured":"Astellas Pharma US, Inc., Medivation, Inc Xtandi Clinical Pharmacology and Biopharmaceutics Review(s) http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf"},{"key":"10.1111\/jcpt.12503-BIB0017|jcpt12503-cit-0017","unstructured":"Astellas Pharma US, Inc Xtandi CHMP assessment report http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002639\/WC500144998.pdf"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12503","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12503\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:02:38Z","timestamp":1671818558000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12503","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}